Sudeep Pharma Limited is set to launch its IPO with a total issue size of ₹895 crores through a book building process.
The New IPO consists of a fresh issue of 0.16 crore shares aggregating ₹95 crores and an offer for sale (OFS) of 1.35 crore shares aggregating ₹800 crores.
Sudeep Pharma IPO Price Band, Lot Size & Investor Categories
- Price Band: ₹563 to ₹593 per share
- Lot Size: 25 shares (retail minimum investment approximately ₹14,825 at upper price)
- Investment for sNII: Minimum 14 lots (350 shares) costing about ₹2,07,550
- Investment for bNII: Minimum 68 lots (1,700 shares) costing about ₹10,08,100
- Issue Type: Bookbuilding IPO with a mix of fresh issue and OFS
- Reservation: QIB shares capped at 50%, Retail at minimum 35%, NII at minimum 15%
Key Dates for Sudeep Pharma IPO
| Activity | Date |
|---|---|
| IPO Open Date | November 21, 2025 |
| IPO Close Date | November 25, 2025 |
| Basis of Allotment | November 26, 2025 |
| Refunds Initiation | November 27, 2025 |
| Credit to Demat Account | November 27, 2025 |
| Listing Date | November 28, 2025 |
| UPI Mandate Cutoff Time | 5 PM, November 25, 2025 |
Sudeep Pharma IPO GMP
Here is the table showing Sudeep Pharma IPO GMP based on Sauda and Kostak rates, including GMP values, Sub2 Sauda rates, estimated listing prices, and approximate estimated profits:
| Date | Issue price | GMP | Sub2 Sauda Rate | Estimated Listing Price |
|---|---|---|---|---|
| 2025-11-21 | 593 | ₹20 | ₹1000/ 14000 | ₹613 (Upper Band + GMP) |
| 2025-11-20 | 593 | ₹15 | ₹900/ 13000 | ₹608 (Upper Band + GMP) |
| 2025-11-19 | 593 | ₹10 | ₹800/ 12000 | ₹603 (Upper Band + GMP) |
| 20.25-11-18 | 593 | 0 | 0 | 0 |
This table reflects market activity patterns and expected returns for retail and high net worth investors based on the grey market and Sauda/Kostak rates for Sudeep Pharma IPO.
About Sudeep Pharma Limited Business and Competence
Established in 1989, Sudeep Pharma Limited is a key manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, catering to over 100 countries globally.
With six manufacturing facilities and combined capacity of 50,000 MT, the company specializes in minerals like calcium, iron, magnesium, zinc, potassium, and sodium, supplying over 200 products to customers across pharma, food, and nutrition sectors.
Sudeep Pharma’s strong in-house research and development capabilities focus on innovation and quality control in mineral salts and excipients.
Financial Highlights (Last 3 Years)
| Metric | Fiscal 2022 | Fiscal 2023 | Nine Months FY 2024 (Dec 31) | Comment |
|---|---|---|---|---|
| Revenue from Operations (₹m) | 3,446.18 | 4,287.39 | 3,444.52 | Increasing revenue |
| EBITDA (₹m) | 751.50 | 986.42 | 1,367.43 | Healthy margin growth |
| EBITDA Margin (%) | 21.81% | 23.01% | 39.70% | Margin improvement |
| Profit After Tax (₹m) | 497.99 | 623.21 | 945.44 | Margin expansion |
| Return on Net Worth (%) | 30.38% | 27.54% | 20.85% | Strong returns |
| Net Worth (₹m) | 1,639.22 | 2,262.93 | 4,533.62 | Equity base growing |
Objects of the Offer: How IPO Proceeds Will Be Used
- The majority of net proceeds will fund capital expenditure towards machinery procurement at the Nandesari manufacturing facility
- Remaining funds will be used for general corporate purposes to support growth and expansion
Promoter and Shareholding Details
The promoters include Sujit Jaysukh Bhayani, Avani Sujit Bhayani, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani HUF, Riva Resources Private Limited, and Bhayani Family Trust.
- Pre-IPO promoter holding: 89.37%
- Post-IPO promoter holding (post-dilution): 76.15%
Competitive Strengths
- Market leader with a diversified product portfolio in a high-entry barrier industry
- Established and wide global customer base with high retention and long-term relationships
- Regulatory compliant, high-quality manufacturing facilities
- Focused R&D with well-equipped labs and pilot-scale production
Cash Flow and Debt
- The company has utilized financing from term and working capital loans but is focused on maintaining healthy cash flows from operations to service debt.
- Cash inflows and outflows align with scaling operations; however, maintaining debt covenants will be critical going forward.
Risk Factors
- Customer concentration risk with the top 10 customers contributing over 35% of revenues.
- Exposure to fluctuations in raw material prices and supply chain risks.
- Operational risks related to manufacturing facilities concentrated in a single region.
- Regulatory and environmental compliance risks specific to chemical and pharmaceutical sectors.
- Risks of intellectual property infringement and protection.
Related Party Transactions
- Some related party transactions in line with normal business operations are disclosed and conducted at arm’s length.
Peer Comparison & Valuation
- The company’s financial leverage and profitability ratios indicate robust operational efficiency versus peer companies in specialty chemicals and battery material suppliers.
- Growth prospects tied to India’s battery and EV ecosystem expansion.
Red Flags
- Moderate debt levels with ongoing capital expenditure.
- Dependence on a few major customers.
- Sensitivity to raw material cost volatility.
Why Invest in Sudeep Pharma Limited IPO?
The company’s leadership position in pharmaceutical and specialty ingredients, combined with robust financial metrics, low leverage, and growth-focused capital expenditure, presents a promising investment opportunity.
The steady expansion in revenue and profit margins and strong RoNW are attractive fundamentals for growth investors looking to gain exposure in the specialty chemical and pharma ingredient sectors.
Essential IPO Insights for Investors
To make the most informed decision about the Sudeep Pharma IPO, prospective investors should also understand:
- How to analyze IPO documents including the DRHP.
- The significance of grey market premium (GMP) in IPO pricing and listing.
- SEBI rules for IPO applications and multiple demat accounts.
- What happens during IPO allotment oversubscription and common allotment rejection reasons.
- How to fix recurring UPI errors during IPO subscription.
